Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Jahr

2017

Autoren

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Ziemssen T, Kappos L; OPERA I and OPERA II Clinical Investigators.

Verlag

N Engl J Med. 2017 Jan 19;376(3):221-234.

Link

https://doi.org/10.1056/nejmoa1601277

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

MS brain health quality standards: a survey on the reality in clinical practice in Germany

Best supportive care for patients with primary progressive multiple sclerosis (PPMS) in Germany prior to ocrelizumab treatment: Final results from the RETRO PPMS study

Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION Study

Eculizumab Use in Neuromyelitis Optica Spectrum Disorders

Higher effect sizes for the detection of accelerated brain volume loss and disability progression in multiple sclerosis using deep-learning